243 related articles for article (PubMed ID: 34197269)
1. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
Janssen QP; Buettner S; Suker M; Beumer BR; Addeo P; Bachellier P; Bahary N; Bekaii-Saab T; Bali MA; Besselink MG; Boone BA; Chau I; Clarke S; Dillhoff M; El-Rayes BF; Frakes JM; Grose D; Hosein PJ; Jamieson NB; Javed AA; Khan K; Kim KP; Kim SC; Kim SS; Ko AH; Lacy J; Margonis GA; McCarter MD; McKay CJ; Mellon EA; Moorcraft SY; Okada KI; Paniccia A; Parikh PJ; Peters NA; Rabl H; Samra J; Tinchon C; van Tienhoven G; van Veldhuisen E; Wang-Gillam A; Weiss MJ; Wilmink JW; Yamaue H; Homs MYV; van Eijck CHJ; Katz MHG; Groot Koerkamp B
J Natl Cancer Inst; 2019 Aug; 111(8):782-794. PubMed ID: 31086963
[TBL] [Abstract][Full Text] [Related]
3. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
[TBL] [Abstract][Full Text] [Related]
6. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
[TBL] [Abstract][Full Text] [Related]
7. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence.
Chaudhari VA; Mitra A; Gupta V; Ostwal V; Ramaswamy A; Engineer R; Sirohi B; Shetty N; Bal M; DeSouza A; Bhandare MS; Shrikhande SV
Surgery; 2022 May; 171(5):1388-1395. PubMed ID: 34922745
[TBL] [Abstract][Full Text] [Related]
9. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
10. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
[TBL] [Abstract][Full Text] [Related]
12. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer.
Yoshitomi H; Sakai N; Kagawa S; Takano S; Ueda A; Kato A; Furukawa K; Takayashiki T; Kuboki S; Miyzaki M; Ohtsuka M
Langenbecks Arch Surg; 2019 Jun; 404(4):451-458. PubMed ID: 30868241
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576
[TBL] [Abstract][Full Text] [Related]
16. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
[TBL] [Abstract][Full Text] [Related]
17. Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX.
Park J; Kim HY; Na HY; Lee JS; Lee JC; Kim JW; Yoon YS; Hwang JH; Han HS; Kim J
J Cancer Res Clin Oncol; 2023 May; 149(5):1765-1775. PubMed ID: 35723728
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.
Roselló S; Pizzo C; Huerta M; Muñoz E; Aliaga R; Vera A; Alfaro-Cervelló C; Jordá E; Garcés-Albir M; Roda D; Dorcaratto D; Tarazona N; Torondel S; Guijarro J; Sánchiz V; Gambardella V; Fleitas-Kanonnikoff T; Lluch P; Pascual I; Ferrández A; Sabater L; Cervantes A
ESMO Open; 2020 Nov; 5(6):e000929. PubMed ID: 33229503
[TBL] [Abstract][Full Text] [Related]
20. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T
Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
